News
--(BUSINESS WIRE)--Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, today announced the initiation of a Phase 1b multiple ascending dose study of UPB ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback